Allergy Therapeutics plc - Trading Update and Successful Litigation Settlement
June 27, 2019 10:26 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Trading Update and Successful Litigation Settlement 2019 full year earnings expected to be ahead of market expectations 27 June...
Allergy Therapeutics Publishes New Research Exploring Potential of its Adjuvant Systems in the Treatment of Cancer in the Journal of ImmunoTherapy of Cancer
May 07, 2019 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Allergy Therapeutics Publishes New Research Exploring Potential of its Adjuvant Systems in the Treatment of Cancer in the Journal of...
Allergy Therapeutics PLC: Trading Update
July 12, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Group”) Trading update Group’s market share continues to grow 12 July 2018 Allergy Therapeutics plc (AIM: AGY), the fully integrated...
Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
June 25, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc (“Allergy Therapeutics” or the “Group”) Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in...
Allergy Therapeutics plc - Positive new data with house-dust mite immunotherapy
May 29, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc("Allergy Therapeutics", the “Group” or “Company") Positive new clinical data with house-dust mite immunotherapy ~ House-dust mite immunotherapy shown to be well-tolerated...
Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
May 21, 2018 07:01 ET
|
Allergy Therapeutics
Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study - Primary...
Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant, Microcrystalline Tyrosine (MCT®), in The Journal of Immunology
May 14, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Allergy Therapeutics Publishes New Data Validating Mode of Action and Unique Adjuvant Properties of its Patented Adjuvant,...
Allergy Therapeutics: Interim Results for the six months ended 31 December 2017
March 07, 2018 07:00 ET
|
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0930 GMT...
Allergy Therapeutics: Completion of recruitment in PQ Grass Phase II trial
February 12, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 ...
Allergy Therapeutics: Trading Update
January 31, 2018 07:00 ET
|
Allergy Therapeutics
Allergy Therapeutics plc("Allergy Therapeutics" or the "Group") Trading Update Market share gains driving top line growthStrong cash position sustained by good performance. 31 January 2017...